Would Warren Buffett buy Medibank Private Ltd?

How does Medibank Private Ltd (ASX:MPL) stack up alongside Buffett's investment criteria?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

What would it take to get 'The Oracle of Omaha', Warren Buffett, running the ruler over Medibank Private Ltd (ASX: MPL)?

I've combined his 'rules for acquisitions' (contained in Berkshire Hathaway's annual reports) with his 'four principles' for investments which he also mentions semi-regularly in his reports. Just how does Medibank stack up against these criteria?

  1. Large purchases

Medibank has a market cap of $6 billion, so I think it fits.

  1. Demonstrated consistent earning power

Insurers' profits can be lumpy, but short-tail health insurance enjoys strong demand and is less likely to get caught out by unexpected disasters than QBE Insurance Group Ltd (ASX: QBE) and Insurance Australia Group Ltd (ASX: IAG). Buffett built his success on insurers, so I've given Medibank the benefit of the doubt.

  1. Businesses earning good returns on equity while employing little or no debt

Based on its most recent annual report, Medibank had a respectable return on equity (Net Profit After Tax divided by Total Equity) of around 27%. It also has no debt. Tick.

  1. Management in place

Publicly listed company so, tick. New CEO Craig Drummond and his team would be assessed by Berkshire before any investment was considered, however.

  1. Simple businesses

Again, tick. Some of the policies can get complex but all of the information necessary to understand Medibank is available either from the company, the Australian Bureau of Statistics (ABS), or market intelligence companies like Nielsen.

  1. An offering price

Publicly listed company, tick. A complete takeover for Medibank would command an unknown price however, probably significantly higher than today's.

  1. One that we can understand

Insurance company, see #5.  Tick.

  1. With favorable long-term prospects

In addition to no debt and an attractive return on equity, Medibank enjoys tailwinds in the form of an ageing population and increasing demand for healthcare. What's more, it pays attractive dividends and benefits from regulated premium increases every year. Tick.

  1. Operated by honest and competent people

This one's a little difficult to evaluate. We might presume competence by the fact that Medibank staff were specifically hired for their positions, but without any specific evidence either way I'll mark this one a miss.

  1. Available at a sensible price

A 'sensible' price is the sticking point. Despite falling more than 15% since its most recent results, I'm not sure Medibank is standout value today. Its decline in customer numbers only accelerated in the past 6 months and with the company reinvesting in products and systems, it might not be able to achieve the same level of profitability that it has in recent times. Medibank appears cheaper than other insurers, but this might be deserved.

Foolish takeaway

With 8 out of 10 ticks, Medibank doesn't appear to be a Buffett-style investment. What's more, half of those ticks are due to its type of business and its status as a public company – neither of which are unique to Medibank.

Buffett has previously stated an affinity for buying businesses when they are 'on the operating table', so Medibank's competitive troubles are unlikely to faze him. However, he's also stated a preference for businesses with unique products and/or a moat, and Medibank appears to have neither – it sells health insurance, and competitors have been poaching its market share for the past year.

I don't think we can expect a Berkshire investment in Medibank in the near future.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »